Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Etanercept dose reduction versus withdrawal with methotrexate in moderate rheumatoid arthritis after response
NL-OMON31175Phase 4Not yet recruiting
- Sponsor
- Wyeth
- Start
- Nov 2007
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of etanercept and methotrexate in rheumatoid arthritis (RA) (3 arms), sponsored by Wyeth. Planned start Nov 2007; status: not yet recruiting.
02
Drugs
etanerceptmethotrexate
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NL-OMON31175.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON31175.